Evaxion Biotech Balance Sheet Health
Financial Health criteria checks 2/6
Evaxion Biotech has a total shareholder equity of $-4.7M and total debt of $8.6M, which brings its debt-to-equity ratio to -182.9%. Its total assets and total liabilities are $12.9M and $17.6M respectively.
Key information
-182.9%
Debt to equity ratio
US$8.65m
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.58m |
| Equity | -US$4.73m |
| Total liabilities | US$17.62m |
| Total assets | US$12.89m |
Recent financial health updates
Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Financial Position Analysis
Short Term Liabilities: EVAX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EVAX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVAX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EVAX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVAX has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: EVAX is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.